TILS.L Share News (TILS)
TILS Share
TILS Share
TILS Share
TILS Share
TILS
TILS Share
TILS Broker
TILS Directors
TILS Financial
TILS
TILS Short
TILSMon, 03rd Dec 2018 11:51
LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.
The company explained that the study is a six-month trial to evaluate the tolerability and anti-tumor activity of its small molecule inhibitor, Milciclib, in liver cancer.
The company expects top line data from the trial in the second quarter of 2019.
Tiziana shares were trading up 6.3% at 67.50 pence each.
LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday said Non-Executive Director Riccardo Dalla-Favera has resigned from his role."The company is grateful to Favera for his
Read more
(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that patient enrolment in its ongoing Phase 2a clinical trial, known as CDKO-125A-010, was now completed.
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it began the first in-human trial of Foralumab, a treatment for autoimmune diseases.The biotechnology company said the a
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has priced its underwritten public offering in the US of 442,910 American Depositary Shares representing ordinary shares in
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has commenced underwritten public offering in the US of American Depositary Shares representing ordinary shares in the UK of
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC on Monday reported a flat loss in the first half of 2018 as expenses were broadly unchanged, while the biotechnology firm also announced that its
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC said Friday that Panetta Partners Ltd, a company associated with Chairman Gabriele Cerrone, bought shares in the company worth acquired 469,766 a
Read more(Sharecast News) - Tiziana Life Sciences on Thursday submitted an application to initiate phase one clinical trials for a new treatment of neurodegenerative diseases to the US food and drug administration.
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC said Friday it filed a registration statement with the US Securities Exchange Commission for a proposed initial public offering of its American
Read moreLONDON (Alliance News) - Biotechnology company Tiziana Life Sciences PLC said Wednesday that the phase 2a trial of Milciclib safety and tolerability in patients with Metastatic Hepatocellular has
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC said Thursday it has raised GBP825,000 from the issue of 1.0 million new shares at a price of 80 pence per share.The cancer and autoimmune
Read moreLONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined
Read more(ShareCast News) - Tiziana Life Sciences, the clinical stage biotechnology company, announced that new data has demonstrated the potential of its novel oral therapy with foralumab for non-alcoholic steatohepatitis (NASH), diabetes and other life threatening inflammatory diseases. Oral efficacy in hu
Read more(ShareCast News) - Tiziana Life Sciences has purchased key assets from Sardinia-based biobanking and genomics research company Shardna for €258,000, giving it access to the genetic data of nearly 13,000 people from the Ogliastra region, where life expectancy is high. The AIM-listed clinical stage bi
Read more
